Breakthrough in Cancer Treatment: SCG Cell Therapy's Next-Generation HPV-Specific TCR T Cell Therapy
July 4, 2024, 9:54 pm
National Cancer Institute (NCI)
Location: United States, Maryland, Bethesda
Employees: 1001-5000
Founded date: 1937
SCG Cell Therapy, a biotech company, has received FDA clearance for SCG142, a cutting-edge TCR T cell therapy for HPV-associated solid tumors. This innovative treatment shows promise in revolutionizing cancer care.
SCG Cell Therapy's SCG142 is a game-changer in cancer treatment. With FDA approval, this therapy targets HPV-associated solid tumors, offering hope to patients facing this challenging diagnosis.
SCG142, armed with a TGFβRII-41BB chimeric switch receptor, is a high-avidity HPV-specific TCR that has shown remarkable results in preclinical studies. It demonstrates dual CD8 and CD4 TCR T cell proliferation, inhibiting tumor growth and promoting long-term memory T cell persistence.
Dr. Ke Zhang, SCG Cell Therapy's Chief Scientific Officer, highlights the significance of SCG142's design. By overcoming the hostile tumor microenvironment, this therapy converts inhibitory signals into co-stimulatory ones, paving the way for effective immunotherapy in solid tumors.
HPV, a common sexually transmitted infection, is a major contributor to various cancers. SCG Cell Therapy's focus on developing immunotherapies for HPV-associated cancers underscores the urgent need for innovative treatments in this field.
SCG Cell Therapy's proprietary GianTCRTM platform and AutocellTM manufacturing system position the company as a leader in TCR-based cellular immunotherapy. Their commitment to research, development, and clinical trials showcases their dedication to advancing cancer care.
In a world where HPV-related cancers cause significant morbidity and mortality, SCG Cell Therapy's breakthrough with SCG142 offers a beacon of hope. This next-generation therapy has the potential to transform the landscape of cancer treatment, providing new avenues for patients to combat this challenging disease.
For more information about SCG Cell Therapy and their groundbreaking work in cancer treatment, visit www.scgcell.com.
SCG Cell Therapy's SCG142 is a game-changer in cancer treatment. With FDA approval, this therapy targets HPV-associated solid tumors, offering hope to patients facing this challenging diagnosis.
SCG142, armed with a TGFβRII-41BB chimeric switch receptor, is a high-avidity HPV-specific TCR that has shown remarkable results in preclinical studies. It demonstrates dual CD8 and CD4 TCR T cell proliferation, inhibiting tumor growth and promoting long-term memory T cell persistence.
Dr. Ke Zhang, SCG Cell Therapy's Chief Scientific Officer, highlights the significance of SCG142's design. By overcoming the hostile tumor microenvironment, this therapy converts inhibitory signals into co-stimulatory ones, paving the way for effective immunotherapy in solid tumors.
HPV, a common sexually transmitted infection, is a major contributor to various cancers. SCG Cell Therapy's focus on developing immunotherapies for HPV-associated cancers underscores the urgent need for innovative treatments in this field.
SCG Cell Therapy's proprietary GianTCRTM platform and AutocellTM manufacturing system position the company as a leader in TCR-based cellular immunotherapy. Their commitment to research, development, and clinical trials showcases their dedication to advancing cancer care.
In a world where HPV-related cancers cause significant morbidity and mortality, SCG Cell Therapy's breakthrough with SCG142 offers a beacon of hope. This next-generation therapy has the potential to transform the landscape of cancer treatment, providing new avenues for patients to combat this challenging disease.
For more information about SCG Cell Therapy and their groundbreaking work in cancer treatment, visit www.scgcell.com.